Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2024 | EMBOLISE: middle meningeal artery embolization to prevent the recurrence of subdural hematoma

Jason Davies, MD, PhD, State University of New York (SUNY) at Buffalo, Buffalo, NY, discusses the results of the EMBOLISE trial (NCT04402632), examining the use of middle meningeal artery embolization for treatment of symptomatic subacute or chronic subdural hematoma (SDH). The EMBOLISE trial assessed the use of Onyx™ Liquid Embolic System embolization as an adjunct to surgical treatment, compared to surgical treatment alone. There was a significant benefit of embolization, showing a 3-fold reduction in the rate of return to the operating room, compared to those who did not receive embolization. This finding is supported by comparable results in the MAGIC-MT (NCT04700345) and STEM (NCT04410146) trials. Taken together, these findings are likely to fuel a paradigm shift in the treatment of subdural hematoma. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.